DOCS Stock Price Today (May 2026) — Doximity, Inc. Analysis & Key Metrics 2026-05-22
Doximity, Inc. (DOCS) is trading at $19.94, up 2.84% today (as of May 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $37.77 (89.4% upside).
- Volatility remains elevated (108.49% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.80% YoY) alongside significant competitive pressures.
DOCS Stock Analysis: Key Metrics & Valuation (May 2026)
Concise, actionable data for investors
Doximity, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $4.02B
P/E Ratio
Forward P/E: 16.16
Revenue Growth
Year over Year
Analyst Target
+89.4% upside potential
Key Investor Questions About DOCS
What investors need to know before buying
Based on current market data, DOCS presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 36.78)
- Fundamentals say: Looking solid (debt and growth supportive)
DOCS's growth trajectory depends on its ability to expand within the Health Information Services sector while managing margin pressures.
- Future growth will depend on performance in core Health Information Services operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for DOCS investors include debt exposure and competitive dynamics in the Health Information Services industry.
- $10.69M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Health Information Services.
52-Week Trading Range
Over the past year, DOCS stock traded between $20.55 and $76.51—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 108.49% annualized volatility and β=1.35, the stock exhibits high sensitivity to market moves—making DOCS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
5 Revealing Analyst Questions From Doximity’s Q1 Earnings Call
Doximity’s first quarter results were met with a sharply negative market reaction, as management pointed to a combination of elevated AI-related expenses and persistent caution among pharmaceutical customers. CEO Jeffrey Tangney cited rapid uptake of Doximity’s AI workflow tools by physicians and highlighted a notable increase in engagement, but acknowledged that macro uncertainty and shorter-term spending commitments from clients weighed on the business. Management also addressed the drag on pr
Doximity Leadership Shift And AI Push Reframe Growth And Valuation Outlook
Doximity (NYSE:DOCS) has reshaped its leadership team, appointing a new Chief Financial Officer and President with backgrounds in digital health and technology. The company is deepening its focus on healthcare AI by integrating its Clinical AI Suite, including Scribe and Ask, into Aledade’s national value-based care network. These changes come as Doximity responds to macroeconomic headwinds and shifting pharma advertising dynamics. Doximity runs a digital platform designed for clinicians,...
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.
OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.
Why Are Doximity (DOCS) Shares Soaring Today
Shares of medical professional network Doximity (NYSE:DOCS) jumped 7% in the afternoon session after the company's shares rebounded from a steep sell-off triggered by its weak financial guidance and mixed fourth-quarter results.
Doximity (DOCS) Q1 CY2026 Deep Dive: AI Investments Accelerate Amid Macro and Policy Headwinds
Medical professional network Doximity (NYSE:DOCS) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 5.1% year on year to $145.4 million. On the other hand, next quarter’s revenue guidance of $151.5 million was less impressive, coming in 1.1% below analysts’ estimates. Its non-GAAP profit of $0.26 per share was 7.9% below analysts’ consensus estimates.
Why Doximity (DOCS) Shares Are Sliding Today
Shares of medical professional network Doximity (NYSE:DOCS) fell 25.9% in the afternoon session after the company reported underwhelming first quarter results: its revenue guidance for next year revealed a significant slowdown in demand and its full-year revenue guidance fell short of Wall Street's estimates.
Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the wreckage. But here’s what you should actually be watching. The Q1 2026 release on May 11, 2026 was a fracture. EPS came in ... Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product progress is exactly the kind of setup retail investors should scan for: real revenue, real partnerships, and prices low enough that a successful ... 7 Healthcare AI Stocks Under $50 With Huge Upside Potential
Another Wall Street analyst slashes Doximity stock price outlook
Doximity (DOCS) investors are watching one of the steepest sell-side resets the stock has seen in years. In the 24 hours after Doximity released its fiscal fourth-quarter results and fiscal 2027 outlook on May 13, more than 10 Wall Street firms either downgraded the stock, slashed their price ...
Frequently Asked Questions
Common investor questions about Doximity, Inc.
Doximity, Inc. (DOCS) is currently trading at $19.94. The RSI (14-day) is at 36.8, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $37.77 implies 89.4% upside from current levels. Volatility is high at 108.5% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Doximity, Inc. (DOCS): The trailing P/E ratio is 22.01, which is in line with broader market averages. The forward P/E is 16.16, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.68, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 4.95. Price-to-Sales is 7.73. Valuation should be compared to Health Information Services industry peers for context, as different sectors trade at different multiples.
Based on 22 analysts covering DOCS, the consensus price target is $37.77. This represents a 89.4% upside from the current price of $19.94. The range spans from a low target of $25.00 to a high target of $55.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Doximity, Inc. (DOCS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Doximity, Inc. (DOCS) investors include: 1. High volatility (108.5% annualized)—the stock can experience significant daily price swings. 2. Elevated short interest (11.5% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Health Information Services sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Doximity, Inc.'s (DOCS) current debt and financial health profile: Total debt stands at $10.69M. The debt-to-equity ratio is 1.09, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 6.63, indicating strong short-term liquidity. The quick ratio is 6.00. The company holds $735.13M in cash and equivalents. Free cash flow is positive at $213.63M, providing a cushion for debt servicing and shareholder returns.